Amarantus BioScience Holdings, Inc.

655 Montgomery Street, Suite 900
San Francisco, CA 94107 USA
Phone
Fax
Click for website

Research Sector Biotechnology; Pharmaceutical; Diagnostics

Summary Description Biotechnology company that develops modifying treatments to address cell death.

Management Gerald E. Commissiong, President and Chief Executive Officer; John W. Commissiong, PhD, Chief Scientific Officer; Robert Farrell, J.D., Chief Financial Officer; Charlotte Keywood, MD., Chief Medical Officer, Therapeutics Division; Marc E. Faerber, Corporate Controller and Vice President of Financial Operations; Kerry Segal, Head of Business Development; Tiffini Clark, Head of Operations and Regulatory Affairs; F. Randall Grimes, Head of Sponsored Research; Paul Jorgensen, Head of Diagnostics Product Development; Mark Wakefield, Head of Clinical Development

Click here for Financial Data
Keywords: Parkinsons Disease, apoptosis, neurodegenerative diseases, Myocardial Infaraction, brain health, diagnostics, Alzheimer's, ADHD

Comment


Updated: Nov. 29, 2016


Description

Amarantus Biosciences Pioneering the development of a novel therapeutic protein that has neuron-protective properties - termed MANF - which has the potential to serve as a first-in-class treatment for......view more

Products / Services

The most advanced drug candidate, AMRS001, is a growth factor indicated for the treatment of Parkinsons Disease and Myocardial Infarction. Parkinsons Disease generates over $2B in sales annually, and ......view more

Technology / Differentiation

Discovered from Amarantus proprietary Discovery Engine for Secreted Proteins (DESP), AMRS001, also known as MANF, is a highly potent, neurotrophic factor currently in pre-clinical development for the ...view more

Market / Customers

5.2 MM Americans with Alzheimer's Disease; 200k under 65 with younger-onset Alzheimers. By 2025, the number of people with Alzheimers expected to reach 7.1 MM. At least 500k people with PD and ~50......view more


Competitors / Substitutes / Alternatives

There are two broad categories of diagnostics for AD and PD being pursued genetic and molecular (proteins/biomarkers). Both diagnostics utilize patient material obtained from tissue, blood, urine, ...view more

Strategy

Amarantus business strategy, is to discover clinically relevant secreted human proteins, each with the potential to address several critically important medical indications, using our Discovery Engine...view more

RELATED COMPANIES